Sign In
Buy NKTR
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
08:44am, Sunday, 15'th Mar 2026
NEW YORK, March 15, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASDAQ:
New York, New York--(Newsfile Corp. - March 14, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therape
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options
Nektar Therapeutics (NASDAQ:NKTR) Hits New 1-Year High Following Better-Than-Expected Earnings
01:13am, Saturday, 14'th Mar 2026
Nektar Therapeutics (NASDAQ: NKTR - Get Free Report)'s share price reached a new 52-week high during trading on Friday after the company announced better than expected quarterly earnings. The stock tr
New York, New York--(Newsfile Corp. - March 13, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therap
NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therapeutics (NASD
Law Offices of Howard G. Smith Encourages Nektar Therapeutics (NKTR) Shareholders To Inquire About Securities Fraud Class Action
02:36pm, Friday, 13'th Mar 2026
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Nektar Therapeutics (“Nektar” or the “Com
Nektar Q4 Earnings & Revenues Trump Estimates, Pipeline in Focus
12:25pm, Friday, 13'th Mar 2026
NKTR Q4 revenues and earnings beat estimates. The company focuses on rezpeg with phase III studies in atopic dermatitis planned for Q2 2026.
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Friday, 13'th Mar 2026
NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nektar T
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
11:12am, Friday, 13'th Mar 2026
LOS ANGELES, March 13, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nektar Therapeutics (“Nektar�
Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Transcript
03:22am, Friday, 13'th Mar 2026
Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Transcript
New York, New York--(Newsfile Corp. - March 12, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Nektar Therap
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
06:36pm, Thursday, 12'th Mar 2026
Nektar Therapeutics (NKTR) came out with a quarterly loss of $1.78 per share versus the Zacks Consensus Estimate of a loss of $2.76. This compares to a loss of $2.25 per share a year ago.
Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
04:15pm, Thursday, 12'th Mar 2026
SAN FRANCISCO, March 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2025. Cash and investments in marketable s
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Nektar Therapeutics
